Alaunos Therapeutics (TCRT) Net Equity Issued and Repurchased (2015 - 2023)
Alaunos Therapeutics' (TCRT) quarterly Net Equity Issued and Repurchased came in at $92000.0 in Q1 2023, down 99.38% on a QoQ basis from $14.7 million in Q4 2022.
Alaunos Therapeutics (TCRT) Net Equity Issued and Repurchased (2015 - 2023) Analysis & Trends
Alaunos Therapeutics (TCRT) has 3 years of Net Equity Issued and Repurchased data on file, last reported at $92000.0 in Q1 2023.
- Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $92000.0 in Q1 2023, while the trailing twelve-month figure through Dec 2023 was $92000.0 (down 99.38% YoY) and the FY2023 annual result came in at $92000.0, down 99.38% from the prior year.
- Net Equity Issued and Repurchased retreated to $92000.0 in Q1 2023, from $14.7 million in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $14.7 million in Q4 2022 to a low of $92000.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Alaunos Therapeutics | 4.28 Mn | 4.16 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 92,000.00 |
| Mar 31, 2023 | 92,000.00 |
| Dec 31, 2022 | 14.72 Mn |
| Dec 31, 2022 | 14.72 Mn |
| Mar 31, 2015 | 94.32 Mn |
| Mar 31, 2015 | 94.32 Mn |